by Fred Dumais | Mar 15, 2023 | News Release
• Fifth consecutive quarter of revenue growth at $13.2 million in Q1-23, up 210% over Q1-22 • Fifth consecutive quarter of adjusted gross profit increase at $4.2 million, up 178% over Q1-22 • Fifth consecutive quarter of adjusted EBITDA loss reduction at $2.2 million,...
by Fred Dumais | Mar 9, 2023 | News Release
MONTREAL, QUEBEC , March 9, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the first quarter ended January 31, 2023...
by Fred Dumais | Feb 7, 2023 | News Release
Quebec public reimbursement coverage to facilitate and expand medication access for Parkinson’s patients in Quebec MONTREAL, QUEBEC , February 7, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company,...
by Fred Dumais | Jan 30, 2023 | News Release
Record quarterly revenues of $12.7 million in Q4-22, up 274% over Q4-21 Record revenues in 2022 of $27.7 million, up 105% over 2021 Record revenues forecasted in Q1-23 Creation of Ophthalmology Business Unit following the addition of XIIDRA® and SIMBRINZA®, expansion...
by Fred Dumais | Jan 26, 2023 | News Release
In the final analysis of the Phase 3 cinical study conducted by Veru Inc., sabizabulin showed a 51.6% reduction in deaths compared to placebo in hospitalized adult patients with moderate to severe COVID-19 who are at high risk for ARDS Sabizabulin also showed a...
by Fred Dumais | Jan 25, 2023 | News Release
MONTREAL, QUEBEC , January 25, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the fourth quarter and year ended...
